Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs
| Autor: | Yasuhito Fujino, Hideyuki Kanemoto, Yuko Goto-Koshino, Kenjiro Fukushima, Hajime Tsujimoto, Masashi Takahashi, Ko Nakashima, Yasuyuki Endo, Koichi Ohno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Nitrosourea
Neutropenia Time Factors Dose Maximum Tolerated Dose nitrosourea canine Antineoplastic Agents Pharmacology chemistry.chemical_compound Dogs Japan Neoplasms Dose escalation Internal Medicine Medicine Animals General Veterinary Dose-Response Relationship Drug business.industry Nimustine phase I medicine.disease Note Clinical trial ACNU cancer chemistry Maximum tolerated dose Toxicity business |
| Zdroj: | The Journal of Veterinary Medical Science |
| ISSN: | 1347-7439 0916-7250 |
| Popis: | Nimustine (ACNU) is an alkylating agent of the nitrosourea and can be an antineoplastic agent in dogs. But, there has been no report on its dose-limiting toxicity (DLT) in dogs. This study was a phase I dose-escalation clinical trial to determine the maximum tolerated dose (MTD) and DLT of ACNU in tumor-bearing dogs. The starting dosage was 25 mg/m2, and subsequent dosages were administered in increments of 5 mg/m2 in cohort of 3 dogs. Eight dogs were included, the MTD was determined to be 25 mg/m2, DLT was neutropenia, and the optimal interval was considered to be 21 days. The data herein provide a basis for the subsequent phase II trial of ACNU in dogs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|